pembrolizumab + paclitaxel + carboplatin + doxorubicin + cyclophosphamide

This drug is a **multi-agent combination chemotherapy and immunotherapy regimen** consisting of pembrolizumab, paclitaxel, carboplatin, doxorubicin, and cyclophosphamide, typically used in oncology for synergistic antitumor effects. - **Pembrolizumab** is a humanized monoclonal antibody against PD-1 (programmed death receptor-1), acting as an immune checkpoint inhibitor to promote T-cell mediated antitumor response[2][4]. - **Paclitaxel** is a microtubule inhibitor that disrupts mitosis. - **Carboplatin** is a platinum-containing alkylating agent causing DNA crosslinking and apoptosis. - **Doxorubicin** is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II. - **Cyclophosphamide** is an alkylating agent interfering with DNA replication. This combination may be used in investigational protocols for aggressive or refractory cancers where the aim is to maximize cytotoxic and immunological tumor control. Similar combinations (typically without all five agents) have been trialed in advanced and recurrent cancer settings, such as endometrial, ovarian, or esophageal cancer[1][3][7]. However, the exact five-drug combination described is not an established standard of care but represents an investigational, multi-modality therapeutic approach.